Supplementary Figure 1 6 HE-50 HE-116 E-1 HE-108 Supplementary Figure 1. Targeted drug response curves of endometrial cancer cells. Endometrial cancer cell lines were incubated with serial dilutions of the targeted therapeutics tested and after 72h cell viability was assessed using elltiter lue., examples of response curves to treatment with GD-0941, PD0325901 and ZD628. The surviving fraction 50 (SF50) relative to untreated control cells was determined (blue dotted line)., E-1 and HE-108 cells are responsive to the allosteric mtor inhibitor Temsirolimus, whereas cells are Temsirolimus resistant. For Temsirolimus, the SF60 (red dotted line) rather than the SF50 (blue dotted line) was determined as the SF50 was often not reached. t least 3 independent experiments in triplicate per cell line/ targeted drug were performed, as indicated by the distinct lines in each graph, and the mean SF50/SF60 of replicate experiments presented in the manuscript.
Supplementary Figure 2 7 N3-* E-1* EN* HE-1- HE-1- HE-108* HE-116* HE-151* HE-251* HE-265* HE-50 HE-59* HE-6* HHU* Ishikawa* MFE-296* MFE-319* * RL95-2* * SNG-M* TEN HE-116 HE-151 HE-251 HE-6 MFE-296 N3- E-1 HE-108 HE-265 Ishikawa RL95-2 EN HE-59 HHU SNG-M HE-1- HE-1- HE-50 70.8% PIK3 54.2% 37.5% KRS 25.0% β-ctin Supplementary Figure 2. Mutational profile and protein expression levels of endometrial cancer cell lines., Distribution and prevalence of, PIK3, and KRS mutations in 24 EE cell lines. olumns represent individual cell lines, rows represent genes, and colored boxes the presence of a mutation. The mutation frequency for each gene is shown on the right., Whole-cell lysates were analyzed by western blotting for and β-actin as loading control. *: -mutant.
Supplementary Figure 3 8 N3- E-1 EN HE-1- HE-1- HE-108 HE-116 HE-151 HE-251 HE-265 HE-50 HE-59 HE-6 HHU Ishikawa MFE-296 MFE-319 RL95-2 SNG-M rps6 p-rps6 Ser235/236 N3- E-1 EN HE-1- HE-1- HE-108 HE-116 HE-151 HE-251 HE-265 HE-50 HE-59 HE-6 HHU Ishikawa MFE-296 MFE-319 RL95-2 SNG-M N3- E-1 EN HE-1- HE-1- HE-108 HE-116 HE-151 HE-251 HE-265 HE-50 HE-59 HE-6 HHU Ishikawa MFE-296 MFE-319 RL95-2 SNG-M KT p-kt Ser473 ERK p-erk Thr202/Tyr204 Supplementary Figure 3. KT, rps6 and ERK activation in endometrial cancer cell lines. Whole-cell lysates were resolved on is- Tris gels and proteins transferred onto Immobilon PVDF fluorescence membranes. Membranes were probed with antibodies against, KT and p-kt simultaneously,, rps6 and p-rps6 simultaneously, and, ERK and p-erk simultaneously, and detected by conjugated secondary antibodies (IRDye 680LT; IRDye 800W; LI-OR) optimized for near infrared two-color detection at 700nm and 800nm. Membranes were scanned using the Odyssey Infrared Imaging System (LI-OR) and quantified using the 500 Odyssey Software.
Supplementary Figure 4 9 ZD8055 PF-04691502 EGFR KRS H/NRS PIK3 EGFR KRS H/NRS PIK3 EGFR KRS H/NRS PIK3 ZD6244 Supplementary Figure 4. Response of EE cells to PI3K and RF/MEK/ERK pathway inhibitors and association with mutation pattern., surviving fractions of 50% (SF50s) of 24 EE cell lines treated for 72h with serial dilutions of the mtor kinase inhibitor ZD8055 relative to untreated cells were determined using the elltiter-lue assay, ordered from lowest to highest (mean of at least three independent experiments in triplicate ± SEM). Rows below the chart represent genes, and colored boxes the presence of a mutation., SF50 of the dual mtor/pi3k inhibitor PF-04691502., SF50 of the MEK inhibitor ZD6244.
Supplementary Figure 5 ZD628 PD0325901 Temsirolimus ZD8055 PF-04691502 GD-0941 Staurosporin 10 HE-1- PRP l PRP PRP l PRP SNG-M HE-116 Staurosporin 1µM GD-0941 1µM GD+250nM PD 1µM GD+500nM PD 1µM GD+1µM PD 1µM Temsirolimus 1µM Tems + 1µM PD PRP l PRP PRP l PRP D Supplementary Figure 5. ombination treatment of PI3K and MPK pathway inhibitors., and HE-1- cells were treated for 48h with 1µM of ZD628 (RF), PD0325901 (MEK), Temsirolimus (mtor), ZD8055 (mtor kinase), PF-04691502 (PI3K/mTOR), GD-0941 (PI3K), and for 3h with 1µM Staurosporin as positive control. Western blotting for poly (DP-ribose) polymerase (PRP). l: cleaved., Indicated EE cell lines were treated for 72h with 100nM or 1µM GD-0941(gray) or Temsirolimus (red) alone (open bars) or in combination with 25nm or 250nM PD0325901 (striped bars); cell viability is shown relative to untreated control, set to 100% (mean ± SD)., HE-116 and SNG-M cells were treated for 48h with 1µM GD-0941 or Temsirolimus alone or in combination with indicated concentrations of PD0325901. Western blotting for PRP. D, HE-50 and HE-151 cells were treated for 72h with 100nM or 1µM GD-0941 (gray) or Temsirolimus (blue) alone (open bars), or in combination with 25nm or 250nM PD0325901 (striped bars); apoptosis induction is depicted as ratio of aspase-3/7 activation determined using the po-one assay over cell viability determined using elltiter-lue.
Supplementary Figure 6 11 HE-1- HE-50 HE-1- SNG-M HHU E-1 HE-251 MFE-296 HE-6 sirn KRS KRS KRS KRS KRS KRS KRS KRS KRS KRS KRS KRS KRS Tubulin NI-H460 NI-H727 sirn KRS KRS KRS Tubulin Supplementary Figure 6. sirn-mediated KRS silencing efficiency., six KRS-mutant and six KRS wild-type EE cell lines were transfected with non-targeting sirn pool #2 (i.e. scrambled) or KRS sirn for 72h and cell lysates were probed with KRS and α-tubulin antibodies., two KRS-mutant lung cancer cell lines were transfected with non-targeting sirn pool #2 (i.e. scrambled) or KRS sirn for 48h and cell lysates were probed with KRS and α-tubulin antibodies.
Supplementary Figure 7 12 KRS H/NRS PIK3 GSK2636771 TGX-221 KRS H/NRS PIK3 D ZD6482 66 Supplementary Figure 7., surviving fractions of 50% (SF50s) of 24 EE cell lines treated for 72h with serial dilutions of the p110β isoformspecific inhibitor GSK2636771 relative to untreated cells were determined using the elltiter- lue assay (mean of at least three independent experiments in triplicate ± SEM). Rows below the chart represent genes, and colored boxes the presence of a mutation., SF50 of the p110β isoform-specific inhibitor ZD6482, ordered from lowest to highest in 24 EE cell lines., SF50 of the p110β isoformspecific inhibitor TGX-221, ordered from lowest to highest in 15 EE cell lines. D, SF50 of the p110α isoform-specific inhibitor 66, ordered from lowest to highest in 15 EE cell lines. KRS H/NRS PIK3 KRS H/NRS PIK3
Supplementary Figure 8 13 D Supplementary Figure 8., wild-type and -mutant EE cell lines were treated for 4h with 1µM of the pan-class I PI3K inhibitor GD-0941, p110α inhibitor 66, p110β inhibitors GSK2636771 and ZD6482, alone or in combination. Whole-cell lysates were analyzed by western blotting for total and phosphorylated KT(Ser473) and KT(Thr308), detected by near infrared two-color detection (LI-OR; Odyssey), and quantified., -deficient breast and prostate control cells treated for 4h with indicated concentrations of GD-0941, 66, GSK2636771 or ZD6482; quantification of LI-OR western blot for total and phosphorylated KT(Ser473,Thr308)., Quantification of western blot shown in Figure 4D. D, cell viability was determined after 72h of treatment with indicated concentration of the p110β inhibitors GSK2636771 (left) and ZD6482 (right), alone (blue) or in combination with the p110α inhibitor 66 (red), in p110β reliant breast and prostate cancer cell lines (black), and two wild-type EE cells. Mut: mutant, wt: wild-type.